{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,27]],"date-time":"2025-06-27T09:23:58Z","timestamp":1751016238241,"version":"3.37.3"},"reference-count":35,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2016,10,1]],"date-time":"2016-10-01T00:00:00Z","timestamp":1475280000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100008897","name":"Janssen Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008897","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","dldjournalonline.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Digestive and Liver Disease"],"published-print":{"date-parts":[[2016,10]]},"DOI":"10.1016\/j.dld.2016.06.033","type":"journal-article","created":{"date-parts":[[2016,7,20]],"date-time":"2016-07-20T22:21:18Z","timestamp":1469053278000},"page":"1194-1199","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["von Willebrand factor antigen (vWF-Ag): A non-invasive predictor of treatment response and serious adverse events in HCV patients with interferon triple therapy"],"prefix":"10.1016","volume":"48","author":[{"given":"Karoline","family":"Rutter","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexandra","family":"Etschmaier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Monika","family":"Ferlitsch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andreas","family":"Maieron","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephanie","family":"Hametner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Horvatits","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rafael","family":"Paternostro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Petra","family":"Salzl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Reiberger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Markus","family":"Peck-Radosavljevic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Quehenberger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Harald","family":"Hofer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Trauner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Ferenci","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arnulf","family":"Ferlitsch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.dld.2016.06.033_bib0180","doi-asserted-by":"crossref","first-page":"2405","DOI":"10.1056\/NEJMoa1012912","article-title":"Telaprevir for previously untreated chronic hepatitis C virus infection","volume":"364","author":"Jacobson","year":"2011","journal-title":"New England Journal of Medicine"},{"key":"10.1016\/j.dld.2016.06.033_bib0185","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1056\/NEJMoa1010494","article-title":"Boceprevir for untreated chronic HCV genotype 1 infection","volume":"364","author":"Poordad","year":"2011","journal-title":"New England Journal of Medicine"},{"key":"10.1016\/j.dld.2016.06.033_bib0190","doi-asserted-by":"crossref","DOI":"10.1016\/j.jhep.2013.04.035","article-title":"Triple therapy in treatment-experienced patients with hcv-cirrhosis in a multicentre cohort of the French early access programme (anrs co20-cupic) \u2013 nct01514890","author":"Hezode","year":"2013","journal-title":"Journal of Hepatology"},{"key":"10.1016\/j.dld.2016.06.033_bib0195","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.jhep.2014.08.052","article-title":"Safety profile of boceprevir and telaprevir in chronic hepatitis C: real world experience from HCV-TARGET","volume":"62","author":"Gordon","year":"2015","journal-title":"Journal of Hepatology"},{"key":"10.1016\/j.dld.2016.06.033_bib0200","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/s12985-015-0261-0","article-title":"First-generation protease inhibitor-triple therapy: SVR 24, safety, and predictors of response in a large single center cohort","volume":"12","author":"Werner","year":"2015","journal-title":"Virology Journal"},{"key":"10.1016\/j.dld.2016.06.033_bib0205","article-title":"Recommendations on treatment of hepatitis C 2015","author":"EASL","year":"2015","journal-title":"Journal of Hepatology"},{"key":"10.1016\/j.dld.2016.06.033_bib0210","doi-asserted-by":"crossref","first-page":"602-8e1","DOI":"10.1016\/j.cgh.2011.03.002","article-title":"Portal pressure predicts outcome and safety of antiviral therapy in cirrhotic patients with hepatitis C virus infection","volume":"9","author":"Reiberger","year":"2011","journal-title":"Clinical Gastroenterology and Hepatology: The Official Clinical Practice Journal of the American Gastroenterological Association"},{"key":"10.1016\/j.dld.2016.06.033_bib0215","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1016\/j.jhep.2010.06.004","article-title":"Revising consensus in portal hypertension: report of the Baveno V consensus workshop on methodology of diagnosis and therapy in portal hypertension","volume":"53","author":"de Franchis","year":"2010","journal-title":"Journal of Hepatology"},{"key":"10.1016\/j.dld.2016.06.033_bib0220","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1182\/blood.V94.1.179.413k18_179_185","article-title":"von Willebrand factor propeptide in vascular disorders: a tool to distinguish between acute and chronic endothelial cell perturbation","volume":"94","author":"van Mourik","year":"1999","journal-title":"Blood"},{"key":"10.1016\/j.dld.2016.06.033_bib0225","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/S0168-8278(99)80104-4","article-title":"Von Willebrand factor could be an index of endothelial dysfunction in patients with cirrhosis: relationship to degree of liver failure and nitric oxide levels","volume":"30","author":"Albornoz","year":"1999","journal-title":"Journal of Hepatology"},{"key":"10.1016\/j.dld.2016.06.033_bib0230","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1161\/CIRCULATIONAHA.107.722827","article-title":"von Willebrand factor in cardiovascular disease: focus on acute coronary syndromes","volume":"117","author":"Spiel","year":"2008","journal-title":"Circulation"},{"key":"10.1016\/j.dld.2016.06.033_bib0235","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/S0008-6363(97)00039-4","article-title":"von Willebrand factor: a marker of endothelial dysfunction in vascular disorders?","volume":"34","author":"Lip","year":"1997","journal-title":"Cardiovascular Research"},{"key":"10.1016\/j.dld.2016.06.033_bib0240","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1002\/hep.21231","article-title":"Elevated levels of von Willebrand factor in cirrhosis support platelet adhesion despite reduced functional capacity","volume":"44","author":"Lisman","year":"2006","journal-title":"Hepatology"},{"key":"10.1016\/j.dld.2016.06.033_bib0245","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1002\/hep.25806","article-title":"von Willebrand factor as new noninvasive predictor of portal hypertension, decompensation and mortality in patients with liver cirrhosis","volume":"56","author":"Ferlitsch","year":"2012","journal-title":"Hepatology"},{"key":"10.1016\/j.dld.2016.06.033_bib0250","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1136\/gut.2010.235689","article-title":"Von Willebrand factor levels predict clinical outcome in patients with cirrhosis and portal hypertension","volume":"60","author":"La Mura","year":"2011","journal-title":"Gut"},{"key":"10.1016\/j.dld.2016.06.033_bib0255","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1016\/j.jhep.2014.04.025","article-title":"von Willebrand factor antigen for detection of hepatopulmonary syndrome in patients with cirrhosis","volume":"61","author":"Horvatits","year":"2014","journal-title":"Journal of Hepatology"},{"key":"10.1016\/j.dld.2016.06.033_bib0260","doi-asserted-by":"crossref","first-page":"831","DOI":"10.3851\/IMP1654","article-title":"von Willebrand factor antigen: a novel on-treatment predictor of response to antiviral therapy in chronic hepatitis C genotypes 1 and 4","volume":"15","author":"Pramhas","year":"2010","journal-title":"Antiviral Therapy"},{"key":"10.1016\/j.dld.2016.06.033_bib0265","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1111\/apt.12564","article-title":"Von Willebrand Factor as a new marker for non-invasive assessment of liver fibrosis and cirrhosis in patients with chronic hepatitis C","volume":"39","author":"Maieron","year":"2014","journal-title":"Alimentary Pharmacology & Therapeutics"},{"key":"10.1016\/j.dld.2016.06.033_bib0270","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1002\/hep.510240201","article-title":"An algorithm for the grading of activity in chronic hepatitis C. The METAVIR cooperative study group","volume":"24","author":"Bedossa","year":"1996","journal-title":"Hepatology"},{"key":"10.1016\/j.dld.2016.06.033_bib0275","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1111\/j.1365-2036.2004.02305.x","article-title":"Short- and long-term effects of therapy with interferon-alpha and pegylated interferon-alpha\/ribavirin on platelet plug formation and von Willebrand factor release in patients with chronic hepatitis C","volume":"21","author":"Homoncik","year":"2005","journal-title":"Alimentary Pharmacology & Therapeutics"},{"key":"10.1016\/j.dld.2016.06.033_bib0280","doi-asserted-by":"crossref","first-page":"3429","DOI":"10.1128\/AAC.02497-13","article-title":"SILEN-C3, a phase 2 randomized trial with faldaprevir plus pegylated interferon alpha-2a and ribavirin in treatment-naive hepatitis C virus genotype 1-infected patients","volume":"58","author":"Dieterich","year":"2014","journal-title":"Antimicrobial Agents and Chemotherapy"},{"key":"10.1016\/j.dld.2016.06.033_bib0285","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1053\/j.gastro.2013.10.058","article-title":"Simeprevir increases rate of sustained virologic response among treatment-experienced patients with HCV genotype-1 infection: a phase IIb trial","volume":"146","author":"Zeuzem","year":"2014","journal-title":"Gastroenterology"},{"key":"10.1016\/j.dld.2016.06.033_bib0290","doi-asserted-by":"crossref","first-page":"1918","DOI":"10.1002\/hep.26641","article-title":"Once-daily simeprevir (TMC435) with pegylated interferon and ribavirin in treatment-naive genotype 1 hepatitis C: the randomized PILLAR study","volume":"58","author":"Fried","year":"2013","journal-title":"Hepatology"},{"key":"10.1016\/j.dld.2016.06.033_bib0295","doi-asserted-by":"crossref","first-page":"2143","DOI":"10.1002\/hep.26276","article-title":"Faldaprevir combined with pegylated interferon alfa-2a and ribavirin in treatment-naive patients with chronic genotype 1 HCV: SILEN-C1 trial","volume":"57","author":"Sulkowski","year":"2013","journal-title":"Hepatology"},{"key":"10.1016\/j.dld.2016.06.033_bib0300","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1002\/hep.26274","article-title":"PROPEL: a randomized trial of mericitabine plus peginterferon alpha-2a\/ribavirin therapy in treatment-naive HCV genotype 1\/4 patients","volume":"58","author":"Wedemeyer","year":"2013","journal-title":"Hepatology"},{"key":"10.1016\/j.dld.2016.06.033_bib0305","doi-asserted-by":"crossref","first-page":"1538","DOI":"10.1002\/hep.24549","article-title":"Retreatment with telaprevir combination therapy in hepatitis C patients with well-characterized prior treatment response","volume":"54","author":"Muir","year":"2011","journal-title":"Hepatology"},{"key":"10.1016\/j.dld.2016.06.033_bib0310","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1016\/j.jhep.2014.12.024","article-title":"STARTVerso1: a randomized trial of faldaprevir plus pegylated interferon\/ribavirin for chronic HCV genotype-1 infection","volume":"62","author":"Ferenci","year":"2015","journal-title":"Journal of Hepatology"},{"key":"10.1016\/j.dld.2016.06.033_bib0315","doi-asserted-by":"crossref","DOI":"10.1111\/liv.12799","article-title":"Triple therapy with boceprevir or telaprevir in a European cohort of cirrhotic HIV\/HCV genotype 1-coinfected patients","author":"Miailhes","year":"2015","journal-title":"Liver International: Official Journal of the International Association for the Study of the Liver"},{"key":"10.1016\/j.dld.2016.06.033_bib0320","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1111\/apt.13315","article-title":"Interferon-free regimens for chronic hepatitis C overcome the effects of portal hypertension on virological responses","volume":"42","author":"Mandorfer","year":"2015","journal-title":"Alimentary Pharmacology & Therapeutics"},{"key":"10.1016\/j.dld.2016.06.033_bib0325","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1056\/NEJMoa0908014","article-title":"Telaprevir for previously treated chronic HCV infection","volume":"362","author":"McHutchison","year":"2010","journal-title":"New England Journal of Medicine"},{"key":"10.1016\/j.dld.2016.06.033_bib0330","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1097\/MEG.0000000000000121","article-title":"Limited effectiveness and safety profile of protease inhibitor-based triple therapy against chronic hepatitis C in a real-world cohort with a high proportion of advanced liver disease","volume":"26","author":"Maasoumy","year":"2014","journal-title":"European Journal of Gastroenterology & Hepatology"},{"key":"10.1016\/j.dld.2016.06.033_bib0335","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.jhep.2006.08.020","article-title":"Peginterferon alfa-2b and ribavirin in patients with hepatitis C virus and decompensated cirrhosis: a controlled study","volume":"46","author":"Iacobellis","year":"2007","journal-title":"Journal of Hepatology"},{"key":"10.1016\/j.dld.2016.06.033_bib0340","doi-asserted-by":"crossref","first-page":"4786","DOI":"10.3748\/wjg.v22.i19.4786","article-title":"von Willebrand factor antigen as a therapeutic target of portal hypertension in cirrhosis","volume":"22","author":"Kalambokis","year":"2016","journal-title":"World Journal of Gastroenterology"},{"key":"10.1016\/j.dld.2016.06.033_bib0345","doi-asserted-by":"crossref","first-page":"e0149230","DOI":"10.1371\/journal.pone.0149230","article-title":"The VITRO score (Von Willebrand factor antigen\/thrombocyte ratio) as a new marker for clinically significant portal hypertension in comparison to other non-invasive parameters of fibrosis including ELF test","volume":"11","author":"Hametner","year":"2016","journal-title":"PLOS ONE"},{"key":"10.1016\/j.dld.2016.06.033_bib0350","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1016\/j.addr.2007.07.002","article-title":"Interferon-based therapy of hepatitis C","volume":"59","author":"Chevaliez","year":"2007","journal-title":"Advanced Drug Delivery Reviews"}],"container-title":["Digestive and Liver Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1590865815304333?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1590865815304333?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,11,18]],"date-time":"2022-11-18T18:32:53Z","timestamp":1668796373000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1590865815304333"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,10]]},"references-count":35,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2016,10]]}},"alternative-id":["S1590865815304333"],"URL":"https:\/\/doi.org\/10.1016\/j.dld.2016.06.033","relation":{},"ISSN":["1590-8658"],"issn-type":[{"type":"print","value":"1590-8658"}],"subject":[],"published":{"date-parts":[[2016,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"von Willebrand factor antigen (vWF-Ag): A non-invasive predictor of treatment response and serious adverse events in HCV patients with interferon triple therapy","name":"articletitle","label":"Article Title"},{"value":"Digestive and Liver Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.dld.2016.06.033","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Editrice Gastroenterologica Italiana S.r.l. Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}